SuperworthRelmada Therapeutics EPS RLMD
Diluted earnings per share by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2026
- −$0.96
- Latest quarter, Q2 FY26
- −$0.11
- Fiscal year 2025
- −$1.51
Relmada Therapeutics' earnings per share was −$0.96 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.11.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.51 | n/a |
| FY2024 | −$2.65 | n/a |
| FY2023 | −$3.28 | n/a |
| FY2022 | −$5.30 | n/a |
| FY2021 | −$7.14 | n/a |
| FY2020 | −$3.78 | n/a |
| FY2019 | −$3.06 | n/a |
| FY2019 | −$1.64 | n/a |
| FY2018 | −$2.88 | n/a |
| FY2017 | −$2.08 | n/a |
| FY2016 | −$1.16 | n/a |
| FY2015 | −$11.68 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.11 | n/a | −$0.96 | |
| Q1 FY26 | −$0.22 | n/a | −$1.15 | |
| Q4 FY25 | −$0.33 | n/a | −$1.51 | |
| Q3 FY25 | −$0.30 | n/a | −$1.80 | |
| Q2 FY25 | −$0.30 | n/a | −$2.22 | |
| Q1 FY25 | −$0.58 | n/a | −$2.51 | |
| Q4 FY24 | −$0.62 | n/a | −$2.65 | |
| Q3 FY24 | −$0.72 | n/a | −$2.87 | |
| Q2 FY24 | −$0.59 | n/a | −$2.88 | |
| Q1 FY24 | −$0.72 | n/a | −$3.13 | |
| Q4 FY23 | −$0.84 | n/a | −$3.28 | |
| Q3 FY23 | −$0.73 | n/a | −$3.70 |
Against its peers
Companies in Drug Manufacturers - General nearest Relmada Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RLMDRelmada Therapeutics | −$0.96 | |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Relmada Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.